Analysis updated on Nov. 10, 2026 (UTC) · Total · absolute moveSwitch to Alpha · NYSE
Our AI scores Abbvie Inc. every trading day against every stock it covers. Create a free account and follow it to see its rating and price target.
Abbvie Inc. is a mega-cap company with a market capitalization of $518.30B. It ranks number 3 by market capitalization among the 60 Pharmaceutical Preparations issuers in our coverage with a current forecast.
For ABBV, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 9.0%, measured on 358 forecast dates between 2022-08-23 and 2026-08-12 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is -11.0%, measured on 400 forecast dates between 2022-08-23 and 2026-10-09. Across our coverage, the out-of-sample test on 4629 stocks from 2025-01-06 to 2026-08-04 produced a positive net return in 92.9% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected absolute price move over the horizon, market included. This is the number a price target is built from. Ratings: strong buy ≥ +6.4%, buy ≥ +4.3%, sell < +2.2%, strong sell < +0.6% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-11-09 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, ABBV included.
90D Total forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Pharmaceutical Preparations peers listed below that report each metric.
| Metric | ABBV | Rank |
|---|---|---|
| Market Cap | $518.30B | 3/60 |
| P/E Ratio | 44.92x | 9/32 |
| Dividend Yield | 2.34% | 4/10 |
| EPS | $6.53 | – |
| Revenue/Share | $37.36 | – |
| FCF/Share | $10.68 | – |
| Metric | ABBV | Rank |
|---|---|---|
| ROA | 7.0% | 17/42 |
| ROIC | 20.3% | 9/44 |
| Gross Margin | 73.7% | 22/36 |
| Operating Margin | 32.2% | 7/38 |
| Net Margin | 15.7% | 13/35 |
| EBT Margin | 19.4% | 13/46 |
| Tax Rate | 19.2% | – |
| Metric | ABBV | Rank |
|---|---|---|
| Current Ratio | 0.87x | 56/58 |
| Quick Ratio | 0.75x | 37/43 |
| Interest Coverage | 7.8x | 8/33 |
| Working Capital | -$5.62B | 57/58 |
| Metric | ABBV | Rank |
|---|---|---|
| Operating Cash Flow | $20.09B | 9/59 |
| Free Cash Flow | $18.87B | 7/50 |
| Capital Spending | -$1.22B | 40/50 |
| OCF Growth YoY | -3.7% | 21/34 |
| FCF Growth YoY | -4.1% | 24/32 |
| FCF/Sales | 28.6% | 5/42 |
| CapEx/Sales | 1.8% | 26/42 |
| Metric | ABBV | Rank |
|---|---|---|
| Asset Turnover | 0.45x | 21/39 |
| Receivables Turnover | 4.9x | 21/36 |
| Inventory Turnover | 3.3x | 10/35 |
| Fixed Assets Turnover | 11.1x | 18/41 |
| Days Sales Outstanding | 75 days | 16/36 |
| Days Inventory | 112 days | 26/35 |
| Payables Period | 724 days | 2/24 |
| Cash Conversion Cycle | -538 days | 22/22 |
| Metric | ABBV | Rank |
|---|---|---|
| Total Revenue | $66.01B | 8/46 |
| Operating Income | $21.23B | 6/50 |
| Net Income | $10.34B | 6/46 |
| R&D Expense | $9.96B | 11/58 |
| SG&A Expense | $15.19B | 6/40 |
| Cost of Goods Sold | $17.35B | 10/37 |
| Metric | ABBV | Rank |
|---|---|---|
| Dividends Per Share | $6.87 | – |
| Payout Ratio | 105.2% | 3/10 |
| Shares Outstanding | 1767M | – |
| Net Income Growth | 333.1% | 3/23 |
| EPS Growth | 380.1% | 2/24 |
| Total Current Assets | $37.48B | 25.4% of assets |
| Cash & Short-term Investments | $10.77B | 7.3% of assets |
| Accounts Receivable | $13.51B | 9.1% of assets |
| Inventory | $5.30B | 3.6% of assets |
| Total Liabilities | $152.22B | |
| Short-term Debt | $8.67B | 5.9% of assets |
Companies classified under the same SEC industry code as Abbvie Inc. (Pharmaceutical Preparations): 60 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Total) | Market Cap |
|---|---|---|
| ABBV Abbvie Inc. | $518.30B | |
| LLY Eli Lilly & Co | $1.27T | |
| JNJ Johnson & Johnson | $664.95B | |
| MRK Merck & Co., Inc. | $362.01B | |
| NVS Novartis Ag | $310.17B | |
| AZN Astrazeneca Plc | $293.55B | |
| ABT Abbott Laboratories | $192.16B | |
| NVO Novo Nordisk A S | $179.14B | |
| PFE Pfizer Inc | $167.51B | |
| VRTX Vertex Pharmaceuticals Inc / Ma | $138.67B | |
| BMY Bristol Myers Squibb Co | $127.02B | |
| SNY Sanofi | $115.97B | |
| GSK Gsk Plc | $101.54B | |
| REGN Regeneron Pharmaceuticals, Inc. | $93.11B | |
| TAK Takeda Pharmaceutical Co Ltd | $65.66B | |
| TEVA Teva Pharmaceutical Industries Ltd | $49.65B | |
| ONC Beone Medicines Ltd. | $46.26B | |
| GMAB Genmab A/S | $34.50B | |
| ZTS Zoetis Inc. | $32.81B | |
| RPRX Royalty Pharma Plc | $28.82B | |
| ROIV Roivant Sciences Ltd. | $28.08B | |
| INSM Insmed Inc | $25.10B | |
| UTHR United Therapeutics Corp | $24.11B | |
| VTRS Viatris Inc | $22.87B | |
| ALNY Alnylam Pharmaceuticals, Inc. | $20.98B | |
| ASND Ascendis Pharma A/S | $17.07B | |
| JAZZ Jazz Pharmaceuticals Plc | $15.24B | |
| BBIO Bridgebio Pharma, Inc. | $15.18B | |
| ELAN Elanco Animal Health Inc | $13.41B | |
| SMMT Summit Therapeutics Inc. | $13.03B | |
| RDY Dr Reddys Laboratories Ltd | $12.44B | |
| BMRN Biomarin Pharmaceutical Inc | $11.07B | |
| TGTX Tg Therapeutics, Inc. | $9.49B | |
| MDGL Madrigal Pharmaceuticals, Inc. | $9.23B | |
| SYRE Spyre Therapeutics, Inc. | $9.16B | |
| PTGX Protagonist Therapeutics, Inc | $8.54B | |
| CORT Corcept Therapeutics Inc | $8.11B | |
| PRAX Praxis Precision Medicines, Inc. | $7.75B | |
| ALKS Alkermes Plc. | $7.75B | |
| RYTM Rhythm Pharmaceuticals, Inc. | $7.73B | |
| CYTK Cytokinetics Inc | $7.67B | |
| KNSA Kiniksa Pharmaceuticals International, Plc | $7.37B | |
| AXSM Axsome Therapeutics, Inc. | $7.02B | |
| ARWR Arrowhead Pharmaceuticals, Inc. | $6.96B | |
| ABVX Abivax S.A. | $6.83B | |
| ORKA Oruka Therapeutics, Inc. | $6.81B | |
| AMRX Amneal Pharmaceuticals, Inc. | $6.80B | |
| IONS Ionis Pharmaceuticals Inc | $6.55B | |
| BLTE Belite Bio, Inc | $6.20B | |
| LGND Ligand Pharmaceuticals Inc | $6.12B | |
| MIRM Mirum Pharmaceuticals, Inc. | $6.09B | |
| COGT Cogent Biosciences, Inc. | $5.82B | |
| MANE Veradermics, Inc | $5.80B | |
| SUPN Supernus Pharmaceuticals, Inc. | $5.56B | |
| PTCT Ptc Therapeutics, Inc. | $5.47B | |
| ERAS Erasca, Inc. | $5.04B | |
| DNTH Dianthus Therapeutics, Inc. /De/ | $5.03B | |
| EWTX Edgewise Therapeutics, Inc. | $4.89B | |
| TVTX Travere Therapeutics, Inc. | $4.44B | |
| LEGN Legend Biotech Corp | $4.33B |
AbbVie (ABBV) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Over the past ...
North Chicago, Illinois-based AbbVie Inc. (ABBV) discovers, develops, manufactures, and sells pharmaceuticals worldwide. With ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Our AI scores Abbvie Inc. every trading day against every stock it covers. Create a free account and follow it to see its rating and price target.
For ABBV, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 9.0%, measured on 358 forecast dates between 2022-08-23 and 2026-08-12 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is -11.0%, measured on 400 forecast dates between 2022-08-23 and 2026-10-09. Across our coverage, the out-of-sample test on 4629 stocks from 2025-01-06 to 2026-08-04 produced a positive net return in 92.9% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Abbvie Inc. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Nov. 10, 2026.
60 issuers in our coverage, ABBV included, share the SEC industry code Pharmaceutical Preparations. The largest are: Eli Lilly & Co (LLY), Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), Novartis Ag (NVS), Astrazeneca Plc (AZN), Abbott Laboratories (ABT).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.
Signals, companies, plans: answered from live data.
I read Intratio's daily model signals, company data and your account to answer in seconds, in your language.
